CoChat

Photodynamic therapy for recurrent supratentorial gliomas

Muller, Paul J., Wilson, Brian C. · 1995 · Seminars in Surgical Oncology
Cited by 102

The DOI matches its Crossref record.

Abstract

We have used photodynamic therapy (PDT) in the treatment of 56 patients with recurrent supratentorial gliomas who had failed radiation therapy and who were candidates for palliative reoperation. There were 34 males and 22 females; their mean age was 41 years and the mean Karnofsky score was 79. Thirty‐two patients had glioblastoma multiforme (GBM), 14 had malignant astrocytoma (MA), 6 had malignant mixed glioma (MM), and 4 had ependymoma (EP). Porphyrin photosensitizer was administered intravenously (i.v.) 12–36 hours prior to photoillumination. All patients had the recurrent tumor sub‐totally resected or cyst drained at surgery followed by intraoperative cavitary photoillumination. In 15 cases interstitial photoillumination using fibers with 2 cm diffusing tips supplemented the cavitary illumination. The total light energy delivered ranged from 440 to 4,500 Joules (J) (median = 1,800 J). The energy administered ranged from 120 to 150 J per fiber and the linear energy density ranged from 65 to 450 J/cm. The energy density ranged from 8 to 110 J/cm 2 (median = 38 J/cm 2). There were two postoperative deaths and three patients were left with a persistent increase in their postoperative neurological deficit. The post‐PDT median survival of patients with recurrent GBM was 30 weeks with a 1‐ and 2‐year actuarial survival of 18% and 0%, respectively. The median survival of patients with recurrent GBM from first diagnosis was 118 weeks with a 1‐ and 2‐year actuarial survival of 82% and 57%, respectively. The post‐PDT median survival of patients with recurrent MA was 44 weeks with a 1‐ and 2‐year actuarial survival of 43% and 36%, respectively. The median survival of patients with recurrent MA from first diagnosis was 147 weeks with a 1‐ and 2‐year actuarial survival of 86% and 71%, respectively. Patients with MA who received more than the median light dose had a longer survival than those who received less than the median light dose. Recurrent malignant gliomas have a very poor prognosis. PDT is a successful palliative treatment when they recur and are amenable to further surgical treatment. With increasing light doses, better light delivery systems, and more effective photosensitizers further considerable improvement in survival can be expected. © 1995 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ssu.2980110504

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
Muller, P. J., & Wilson, B. C.
Venue
Seminars in Surgical Oncology
Publisher
Wiley
Published
1995-09
Volume
11
Issue
5
Pages
346-354
ISSN
  • 1098-2388 (ISSN-L)
  • 8756-0437
OpenAlex
W2042172629
Cited by
102
References
0
FWCI
2.27
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.